Search Within

Michael Morris

  1. "Jonathan Rosenberg"
Formats
  1. Meeting Abstract (13)
  2. Journal Article (6)
Groups
  1. Department of Medicine (19)
  2. Genitourinary Oncology Service (19)
  3. Solid Tumor Oncology Division (19)
  4. Department of Pathology and Laboratory Medicine (4)
  5. Epidemiology and Biostatistics (4)
  6. GSK Faculty (4)

More Groups

People
  1. Jonathan Rosenberg (19)
  2. Gopakumar Iyer (7)
  3. Ashley Regazzi (5)
  4. Min Yuen Teo (4)
  5. David Solit (3)
  6. Dean Bajorin (3)

More People

Years
  1. 2025 (3)
  2. 2024 (5)
  3. 2023 (2)
  4. 2022 (5)
  5. 2021 (2)
  6. 2019 (2)
Publications
  1. Journal of Clinical Oncology (13)
  2. Annals of Oncology (1)
  3. Cell (1)
  4. Clinical Genitourinary Cancer (1)
  5. European Urology Open Science (1)
  6. JCO Oncology Practice (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (14)
  2. Cell Press (1)
  3. Elsevier BV (1)
  4. Elsevier Inc. (1)
  5. Massachusetts Medical Society (1)
  6. Oxford University Press (1)

Results (19)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Quality of informed consent via telemedicine compared with in-person for clinical cancer research
    Journal Article

    Sternschuss, M.; Lattanzi, M.; Vertosick, E.; Austria, M.; Martin, S.; Regazzi, A.; Buckely, M. T.; Lengfellner, J.; Riely, G. J.; Solit, D. B.; more...
    JCO Oncology Practice (2025)

    Fulltext@MSK | Save
  • Circulating tumor DNA and response to cisplatin-based chemotherapy in patients with metastatic urothelial carcinoma enrolled in CALGB 90601 (Alliance)
    Journal Article

    Guercio, B. J.; Whiting, K.; Shah, R. H.; Ballman, K. V.; Halabi, S.; Regazzi, A. M.; Milbank, J. H.; Bajorin, D. F.; Beltran, H.; Morris, M. J.; more...
    European Urology Open Science (2025)

    Fulltext@MSK | Save
  • Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma
    Journal Article

    Apolo, A. B.; Ballman, K. V.; Sonpavde, G.; Berg, S.; Kim, W. Y.; Parikh, R.; Teo, M. Y.; Sweis, R. F.; Geynisman, D. M.; Grivas, P.; more...
    New England Journal of Medicine (2025)

    Fulltext@MSK | Save
  • Alliance A031501: AMBASSADOR study of adjuvant pembrolizumab (Pembro) in muscle-invasive urothelial carcinoma (MIUC) vs observation (Obs): Extended follow-up disease-free survival (DFS) results and metastatic (met) disease recurrence distribution
    Meeting Abstract

    Apolo, A. B.; Ballman, K.; Sonpavde, G. P.; Berg, S.; Kim, W.; Parikh, R.; Teo, M. Y.; Sweis, R. F.; Geynisman, D.; Grivas, P.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • MAIN-CAV: Phase III randomized trial of maintenance cabozantinib (CABO) and avelumab (Av) vs Av after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC; Alliance A032001)
    Meeting Abstract

    Gupta, S.; Ballman, K. V.; Apolo, A. B.; Sridhar, S. S.; Chen, R. C.; Wen, Y.; Yen, A. E.; Grivas, P.; Tan, A. L.; Baghaie, S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • AMBASSADOR Alliance A031501: Phase III randomized adjuvant study of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma (MIUC) vs observation
    Meeting Abstract

    Apolo, A. B.; Ballman, K. V.; Sonpavde, G. P.; Berg, S. A.; Kim, W. Y.; Parikh, R. A.; Teo, M. Y.; Sweis, R. F.; Geynisman, D. M.; Grivas, P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A clinical-genetic (CG) circulating tumor DNA (ctDNA)-based prognostic model for predicting overall survival (OS) in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with potent androgen receptor inhibition (Alliance)
    Meeting Abstract

    Halabi, S.; Luo, B.; Guo, S. S.; Knutson, T.; Lyman, J.; Kobilka, A.; Beltran, H.; Antonarakis, E. S.; Rosenberg, J. E.; Galsky, M. D.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 2 trial of ADT interruption in patients responding exceptionally to AR-pathway inhibitor in metastatic hormone-sensitive prostate cancer (A-DREAM/Alliance A032101)
    Meeting Abstract

    Choudhury, A. D.; Heller, G.; Reimers, M. A.; Laccetti, A. L.; Smieliauskas, F.; Ravi, P.; Dooley, K.; Mazza, G. L.; Gartrell, B. A.; Steen, P. D.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC; Alliance A032001)
    Meeting Abstract

    Gupta, S.; Ballman, K. V.; Galsky, M. D.; Morris, M. J.; Sridhar, S. S.; Chen, R. C.; Chan, T. A.; Wen, Y.; Grivas, P.; Tan, A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Alliance A032002 (ART): Phase II randomized trial of atezolizumab versus atezolizumab and radiation therapy for platinum-ineligible/refractory metastatic urothelial cancer
    Meeting Abstract

    Nagar, H.; Ballman, K. V.; Tagawa, S. T.; Tan, A.; Faltas, B. M.; Sheybani, A.; Baghaie, S.; Schwartz, L. H.; Kozono, D. E.; Bogart, J. A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save